π§ͺ Novartis halts cell therapy trials after three deaths
Novartis has decided to pause the trials for its experimental cell therapy following a series of unfortunate events. The halt was initiated after three deaths were reported during the clinical testing phase. These incidents occurred during the ongoing research period, which has been tracked closely by regulatory bodies. The therapy was being tested to offer a new treatment option for certain complex diseases. Moving forward, the company will conduct a thorough safety review before making any further decisions. π§ͺ